СОВРЕМЕННЫЕ АСПЕКТЫ ДИАГНОСТИКИ И ЛЕЧЕНИЯ АНЕМИИ У БОЛЬНЫХ РЕВМАТОИДНЫМ АРТРИТОМ

1. <div><p>Кассирский И.А., Алексеев Г.А. Клиническая гематология. М.: Медицина,1970; 800 с.</p><p>World Health Organization. Nutritional anaemias: Report of a WHO Scientific Group. Geneva: World Health Organization, 1968.</p><p>Wilson A., Reyes E., Ofman J. Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature. Am J Med 2004; 116(7): 44—9.</p><p>Wolfe F., Michaud K. Anemia and renal function in patients with rheumatoid arthritis. J Rheumatol 2006; 33: 1516-22.</p><p>Hochberg M.C., Johnston S.S., John A.K. The incidence and prevalence of extra-articular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006. Curr Med Res Opin 2008; 24(2): 469-80.</p><p>Weiss G., Goodnough L.T. Anemia of chronic disease. New Eng J Med 2005; 352(10): 1011—23.</p><p>Peeters H.R.M., Jongen-Lavrencic M., Raja A.N. et al. Course and characteristics of anemia in patients with rheumatoid arthritis of recent onset. Ann Rheum Dis 1996; 55: 162-8.</p><p>Lipsky P.E., van der Heijde D.M., St. Clair E.W. et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594-602.</p><p>Maini R.N., Breedveld F.C., Kalden J.R. et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthr Rheum 2004; 50: 1051-65.</p><p>Westhovens R., Yocum D., Han J. et al. The safety of infliximab in patients with rheumatoid arthritis with various comorbidities and background treatments: a large, randomized, placebo-controlled trial. Arthr Rheum 2006; 54: 1075-86.</p><p>Nikolaisen C., Figenschau Y., Nossent J.C. Anemia in early rheumatoid arthritis is associated with interleukin 6-mediated bone marrow suppression, but has no effect on disease course or mortality. J Rheumatol 2008; 35(3): 380—6.</p><p>St. Clair E.W., van der Heijde D.M., Smolen J.S. et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthr Rheum 2004; 50: 3432-43.</p><p>Муравьев Ю.В., Галушко Е.А., Кашникова Л.Н. Частота анемии при ревматоидном артрите в 1979,1989 и1999 годах. Науч.-прак-тич ревматол. 2002; 3: 23-6.</p><p>Abe R., Shiga Y., Maruyama Y. A study of anemia and life activity in the elderly. Nippon Ronen Igakkai Zasshi 1994; 31(1): 60—5.</p><p>Zarychanski R., Donald S. Anemia of chronic disease: a harmful disorder or an adaptive, beneficial response? CMAJ 2008; 8(12); 333—7.</p><p>Allaire S.H. Update on work disability in rheumatic diseases. Curr Opin Rheumatol 2001; 13: 93-8.</p><p>Pincus T., Callahan L.F., Sale W.G. et al. Severe functional declines, work disability and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthr Rheum 1984; 27: 864-72.</p><p>Han C., Rahman M.U., Doyle M.K. et al. Association of anemia and physical disability among patients with rheumatoid arthritis. J Rheumatol 2007; 34(11): 2177-82.</p><p>Ershler W.B., Chen K., Reyes E.B., Dubois R. Economic burden of patients with anemia in selected diseases. Value Health 2005; 8: 629-38.</p><p>Silverberg D.S., Iaina A., Wexler D., Blum M. The pathological consequences of anemia. Clin Lab Haematol 2001; 23(1): 1—6.</p><p>Nissenson A.R., Goodnough L.T., Dubois R.W. Anemia: not just an innocent bystander? Arch Intern Med 2003; 163: 1400-4.</p><p>Go A.S., Yang J., Ackerson L.M. et al. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure. The anemia in chronic heart failure: outcomes and resource utilization (ANCHOR) study. Circulation 2006; 6(113): 2713—23.</p><p>Rizzo J.D., Lichtin A.E., Woolf S.H. et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002; 20: 4083-107</p><p>Guralnik J.M., Eisenstaedt R.S., Ferrucci L. et al. The prevalence of anemia in persons age 65 and older in the United States: evidence for a high rate of unexplained anemia. Blood 2004; 104: 2263-8.</p><p>Means R.T. Jr. Recent developments in the anemia of chronic disease. Curr Hematol Rep 2003; 2: 116-21.</p><p>Van Iperen C.E., van de Wiel A., Marx J.J. Acute event-related anaemia. Br J Haematol 2001; 115: 739-43.</p><p>Repping-Wuts H., Fransen J., van Achterberg T. Persistent severe fatigue in patients with rheumatoid arthritis J Clin Nurs 2007; 16(11C): 377—83.</p><p>Wolfe F., Michaud K., Pincus T. Fatigue, rheumatoid arthritis, and anti-tumor necrosis factor therapy: an investigation in 24,831 patients. J Rheumatol 2004; 31: 2115—20.</p><p>Hewlett S. Fatigue in rheumatoid arthritis: from apathy to action. Future Rheumatol 2007; 2(5): 439—42.</p><p>Repping-Wuts H., van Riel P., van Achterberg T. Fatigue in patients with rheumatoid arthritis: what is known and what is needed. Rheumatology (Oxford) 2009; 48(3): 207—9.</p><p>Treharne G.J., Lyons A.C., Hale E.D. et al. Predictors of fatigue over 1 year among people with rheumatoid arthritis. Psychol Health Med 2008; 13(4): 494—504.</p><p>Pollard L.C., Choy E.H., Gonzalez J. Fatigue in rheumatoid arthritis reflects pain, not disease activity. Rheumatology 2006; 45: 885—9.</p><p>Weiss G. Pathogenesis and treatment of anaemia of chronic disease. Blood Rev 2002; 16: 87—96</p><p>Spivak J.L. Iron and the anemia of chronic disease. Oncology (Huntingt) 2002; 16(Suppl. 10): 25—33.</p><p>Demirjian S.G., Nurko S. Anemia of chronic kidney disease: when normalcy becomes undesirable. Cleve Clin J Med 2008; 75(5): 353—6.</p><p>Westenbrink B.D., Voors A.A., van Veldhuisen, D.J. Is anemia in chronic heart failure caused by iron deficiency? J Am Coll Cardiol 2007; 49: 2301—2.</p><p>Cartwright G.E. The anemia of chronic disorders. Semin Hematol 1966; 3: 351—75.</p><p>Hansen N.E. The anaemia of chronic disorders a bag of unsolved questions. Scand J Haematol 1983; 31: 397-402.</p><p>Roodman G.D. Mechanisms of erythroid suppression in the anemia of chronic disease. Blood Cells 1988; 13(1/2): 171—84.</p><p>Ludwiczek S., Aigner E., Theurl I., Weiss G. Cytokine-mediated regulation of iron transport in human monocytic cells. Blood 2003; 101: 4148—54.</p><p>Goodnough L.T., Skikne B., Brugnara C. Erythropoietin, iron, and erythropoiesis. Blood 2000; 96: 823—33.</p><p>Vojdani A. Antibodies as predictors of complex autoimmune diseases. Int J Immunopath Pharm 2008; 21(2): 279—88.</p><p>Jaworski J., Maslinski W., Pazdur J. et al. Decreased expression of integrins by hematopoietic cells in patients with rheumatoid arthritis and anemia: relationship with bone marrow cytokine levels. J Investig Allergol Clin Immunol 2008; 18(1): 17—21.</p><p>Keithi-Reddy S.R., Addabbo F., Patel T.V. et al. Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease. Kidney Int 2008; 74(6): 695—7.</p><p>Torti F.M., Torti S.V. Regulation of ferritin genes and protein. Blood 2002; 99: 3505—16.</p><p>Tilg H., Ulmer H., Kaser A., Weiss G. Role of IL-10 for induction of anemia during inflammation. J Immunol 2002; 169: 2204—9.</p><p>Weiss G. Iron and immunity: a double-edged sword. Eur J Clin Invest 2002; 32(Suppl. 1): 70—8.</p><p>Raj D.S. Role of interleukin-6 in the anemia of chronic disease. Semin Arthr Rheum 2008; 11: 345-9.</p><p>Andrews N.C. Anemia of inflammation: the cytokine-hepcidin link. J Clin Invest 2004; 113: 1251-3.</p><p>Nicolas G., Bennoun M., Porteu A. et al. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci USA 2002; 99: 4596—601.</p><p>Nicolas, G., Chauvet C., Viatte L. et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002; 110: 1037-44.</p><p>Pigeon C., Ilyin G., Courselaud B. et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001; 276(11): 7811—9.</p><p>Laftah A.H., Ramesh B., Simpson R.J. et al. Effect of hepcidin on intestinal iron absorption in mice. Blood 2004; 103: 3940-4.</p><p>Левина А.А., Казюкова Т.В., Цветаева Н.В. и др. Гепсидин как регулятор гомеостаза железа. Педиатрия 2008; 8(1): 67—75.</p><p>Hunter H.N., Fulton D.B., Vogel H.J. The solution structure of human hepcidin, a antibicrobial activity that is involved iniron uptake and hereditary hemochromatosis. J Biol Chem 2002; 277: 37597-603.</p><p>Nemeth E., Valore E.V., Territo M. et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acutephase protein. Blood 2003;101:2461-3.</p><p>Nemeth E., Rivera S., Gabayan V. et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004; 113: 1271-6.</p><p>Ganz T. Hepcidin in iron metabolism. Curr Opin Hematol 2004; 11(4): 251-4.</p><p>Demirag M., Haznedaroglu S.R., Banu S.K. et al. Circulating hepcidin in the crossroads of anemia and inflammation associated with rheumatoid arthritis. Intern Med 2009; 48: 421-6.</p><p>Галушко Е.А., Беленький Д.А., Александрова Е.Н. и др. Роль гепсидина в развитии анемии у больных ревматоидным артритом. Науч-практич ревматол 2012; 3: 19-24.</p><p>Song S.N., Tomosugi N., Kawabata H. et al. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood 2010; 116(18): 3627-34.</p><p>Masson C. Rheumatoid anemia. J Bone Spine 2011; 78(2): 131-7.</p><p>Kim H.R., Kim K.W., Yoon S.Y. et al. Serum pro-hepcidin could reflect disease activity in patients with rheumatoid arthritis. J Korean Med Sci 2010; 25(3): 348-52.</p><p>Jayaranee S., Sthaneshwar P., Sokkalingam S. Serum prohepcidin concentrations in rheumatoid arthritis. Pathology 2009; 41(2): 178-82.</p><p>NKF-K/DOQI Clinical Practice Guidelines for anemia of chronic kidney disease. Am J Kidney Dis 2001; 38: 442.</p><p>Галушко Е.А., Левина А.А., Муравьев Ю.В. Дифференциальная диагностика характера анемии при ревматоидном артрите. Науч.-практич. ревматол. 2003; 3: 23-6.</p><p>Maury C.P., Liljestrom M., Laiho K. et al. Tumor necrosis factor alpha, its soluble receptor I, and -308 gene promoter polymorphism in patients with rheumatoid arthritis with or without amyloidosis: implications for the pathogenesis of nephropathy and anemia of chronic disease in reactive amyloidosis. Arthr Rheum 2003; 48: 3068-76.</p><p>Vreugdenhil G., Wognum A.W., van Eijk H.G., Swaak A.J. Anaemia in rheumatoid arthritis: the role of iron, vitamin B12, and folic acid deficiency, and erytropoietin responsiveness. Ann Rheum Dis 1990; 49: 93-8.</p><p>Minoda M., Horiuchi A. Hematologia abnormalities associated with rheumatoid arthritis. Nippon Rinsho 1992; 50(3): 581-5.</p><p>Margetic S., Topic E., Ruzic D.F., Kvaternik M. Soluble transferrin receptor and transferrin receptor-ferritin index in iron deficiency anemia and anemia in rheumatoid arthritis. Clin Chem Lab Med 2005;43(3):326-31.</p><p>Goyal R., Das R., Bambery P. et al. Serum transferrin receptor-ferritin index shows concomitant iron deficiency anemia and anemia of chronic disease is common in patients with rheumatoid arthritis in north India. Indian J Pathol Microbiol 2008; 51(1): 102-4.</p><p>Внутренние болезни. Под ред. Т.Р. Харрисона. М.: Медицина, 1996; 7: 572-82.</p><p>Teehan G.S., Bahdouch D., Ruthazer R. et al. Iron storage indices: novel predictors of bacteremia in hemodialysis patients initiating intravenous iron therapy. Clin Infect Dis 2004; 38: 1090-4.</p><p>Sullivan J.L. Iron therapy and cardiovascular disease. Kidney Int Suppl 1999; 69: S135-S137.</p><p>Ezekowitz J.A. Anemia in patients with advanced heart failure. J Am Coll Cardiol 2007; 49: 2301.</p><p>Левина А.А., Цветаева Н.В., Колошейнова Т.И. Клинические, биохимические и социальные аспекты железодефицитной анемии. Гематол. трансфузиол. 2001; 46(3): 51—5.</p><p>Ruiz-Argü elles G.J., Diaz-Hernandez А., Manzano C. Ineffectiveness of oral iron hydroxide polymaltose in iron-deficiency anemia. Hematology 2007; 12(3): 255-6.</p><p>Pavai S., Jayaranee S., Sargunan S. Soluble transferrin receptor, ferritin and soluble transferrin receptor - ferritin index in assessment of anaemia in rhaeumatoid arthritis. Med J Malaysia 2007; 62(4): 303-7.</p><p>Punnonen K., Kaipiainen-Seppanen O., Riittinen L. et al. Evaluation of iron status in anemic patients with rheumatoid arthritis using an automated immunoturbidimetric assay for transferrin receptor. Clin Chem Lab Med 2000; 38(12): 1297-300.</p><p>Ravindran V., Jain S., Mathur D.S. The differentiation of anaemia in rheumatoid arthritis: parameters of iron-deficiency in an Indian rheumatoid arthritis population. Rheumatol Int 2008; 28(6): 507—11.</p><p>Pinka P., Lok C.N. The transferrin receptor: role in health and disease. Int J Biochem Cell Biol 1999; 31(10): 1111-37.</p><p>Choi J.W. Serum transferrin receptor concentration and its ratio to bone marrow erythroblasts in iron deficiency anemia and anemia of chronic diseases. Ann Clin Lab Sci 2007; 37(3): 288—90.</p><p>Salvarani C., Baricchi R., Lasagni D. et al. Effects of desferrioxamine therapy on chronic disease anemia associated with rheumatoid arthritis. Rheumatol Int 1996; 16(2): 45—8.</p><p>Heeschen C., Aicher A., Lehmann R. et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003; 102: 1340-6.</p><p>Beaulieu A.D., McKay J.D., Pavelka K. et al. Treatment with the humanized antiinterleukin-6 receptor antibody tocilizumab results in rapid improvements in the signs and symptoms of rheumatoid arthritis: results from a pooled analysis of clinical trial data from OPTION and TOWARD. Ann Rheum Dis 2008; 67(Suppl. II): 195.</p><p>Emery P., Keystone E., Tony H.P. et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008; 67(11): 1516-23.</p><p>Kaltwasser J.P., Kessler U., Gottschalk R. et al. Effect of recombinant human erythropoietin and intravenous iron on anemia and disease activity in rheumatoid arthritis. J Rheumatol 2001; 28: 2430-6.</p><p>Hushaw L.L., Sawaqed R., Sweis G. et al. Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis. Ther Clin Risk Manag 2010; 6: 143-52.</p><p>Patel A.M., Moreland L.W. Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy. Drug Design Dev Ther 2010; 4: 263-78.</p><p>Nishimto N., Ito K., Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol 2010; 20(3): 222—32.</p><p>Singh J.A., Beg S., Lopez-Olivo M.A. Tocilizumab for rheumatoid arthritis: a Cochrane systemic review. J Rheumatol 2011; 38(1): 10—20.</p><p>Kremer J.L., Blanco R., Brzosko M. et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: at 1 year; results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthr Rheum 2011; 63(3): 609—21.</p><p>Kristensen L.E., Jakobsen A.K., Bartels R.M. et al. The number needed to treat for second generation biologics when treating established rheumatoid arthritis: a systemic quantitative review of randomized controlled trials. Scand J Rheumatol 2011; 40(1): 1—7.</p><p>Smolen J.S., Beaulieu A., Rubbert-Roth A. et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008; 371: 987-97.</p><p>Jones G., Sebba A., Gu J. et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis 2010; 69: 88-96.</p><p>Hirabayashi Y., Ishii T., Harigae H. Clinical efficacy of tocilizumab in patients with active rheumatoid arthritis in real clinical practice. Rheum Int 2010; 30(8): 1041—8.</p><p>Yamanaka H., Tanaka Y., Inoue E. et al. Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). Mod Rheumatol 2011; 21(2): 122-33.</p><p>Burmester G.R., Feist E., Kellner H. et al. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with avtive rheumatoid arthritis: the first phase IIIb reallife study (TAMARA). Ann Rheum Dis 2011; 70(5): 755-9.</p><p>Genovese M.C., McKay J.D., Nasonov E.L. et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthr Rheum 2008; 58(10): 2968—80.</p><p>Smolen J.S., Aletaha D. Interleukin-6 receptor inhibition with tocilizumab and attainment of remission: the role of acute phase reactants. Arthr Rheum 2011; 63(1): 43—52.</p><p>Насонов Е.Л., Панасюк Е.Ю., Булдаков С.Г. и др. Эффективность и безопасность тоцилизумаба при ревматоидном артрите (промежуточные результаты российского многоцентрового исследования). Науч.-практич. ревматол. 2010; 2: 21-30.</p><p>Панасюк Е.Ю., Амирджанова В.Н., Александрова Е.Н. и др. Быстрый эффект тоцилизумаба при ревматоидном артрите. Науч.-практич. ревматол. 2011; 4: 11-6.</p><p>Kawabata H., Tomosugi N., Kanda J. Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease. Haematologica 2007; 92(6): 857—8.</p></div><br />